Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XIAP | P98170 | 6/20 | 1.00 |
| ▸ | PSEN1 | P49768 | 6/20 | 0.69 |
| ▸ | PSEN2 | P49810 | 6/20 | 0.69 |
| ▸ | APH1B | Q8WW43 | 6/20 | 0.69 |
| ▸ | NCSTN | Q92542 | 6/20 | 0.69 |
| ▸ | APH1A | Q96BI3 | 6/20 | 0.69 |
| ▸ | PSENEN | Q9NZ42 | 6/20 | 0.69 |
| ▸ | SPPL2A | Q8TCT8 | 6/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15206725 | 1.00 | XIAP (1.00) | XIAPPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL4943515 | 1.00 | XIAP (1.00) | XIAPPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL15206723 | 1.00 | XIAP (1.00) | XIAPPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL15216926 | 1.00 | XIAP (1.00) | XIAPPSEN1PSEN2APH1BNCSTN | |
| Hydrochloric Acid SCHEMBL4939457 | 0.99 | XIAP (0.98) | XIAPPSEN1PSEN2APH1BNCSTN | |
| Hydrochloric Acid SCHEMBL4939467 | 0.99 | XIAP (0.98) | XIAPPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL4942961 | 0.95 | XIAP (0.91) | XIAPPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL15216925 | 0.90 | XIAP (0.82) | XIAPPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL7849704 | 0.87 | XIAP (0.77) | XIAPPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL21577575 | 0.85 | PSEN1 (0.81) | XIAPPSEN1PSEN2APH1BNCSTN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8946224-B2 | Substituted [1,2,4]triazolo[4,3-A]pyrazines for medicaments and pharmaceutical compositions | REDX PHARMA LIMITED (GB) | 2015-02-03 | — | — | US | disclosed |
| EP-2638007-A2 | DRUG DERIVATIVES | Redx Pharma Limited (GB) | 2013-09-18 | — | — | EP | disclosed |
| US-20130225594-A1 | DRUG DERIVATIVES | REDX PHARMA PLC (GB) | 2013-08-29 | — | — | US | disclosed |
| WO-2012063085-A2 | DRUG DERIVATIVES | REDX PHARMA LIMITED (GB) | 2012-05-18 | — | — | WO | disclosed |
| US-7468365-B2 | Lactam compound | ELI LILLY AND COMPANY (US) | 2008-12-23 | — | — | US | disclosed |
| EP-1345955-B1 | LACTAM DIPEPTIDE AND ITS USE IN INHIBITING BETA-AMYLOID PEPTIDE RELEASE | LILLY CO ELI (US) | 2008-08-20 | — | — | EP | disclosed |
| US-20070299053-A1 | Lactam compound | ELI LILLY AND COMPANY | 2007-12-27 | — | — | US | disclosed |
| EP-1353910-B1 | LACTAM COMPOUND | LILLY CO ELI (US) | 2007-05-23 | — | — | EP | disclosed |
| EP-1341531-B1 | LACTAM COMPOUND TO INHIBIT BETA-AMYLOID PEPTIDE RELEASE OR SYNTHESIS | LILLY CO ELI (US) | 2007-01-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225594-A1 | DRUG DERIVATIVES | SQOR, NQO1, CYP2D6 | XIAP 370/4885PSEN1 4212/4885PSEN2 4067/4885 |
| US-20070299053-A1 | Lactam compound | AAAS, ORMDL3, NAALAD2 | XIAP 3446/4885PSEN1 739/4885PSEN2 430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.